glp-1 drugs metformin Ozempic for Type 2 Diabetes: Adding to GLP-1 Medications for Weight Loss:

A network meta-analysis confirmed that adverse events were significantly more frequent with retatrutide (relative risk 4.10) compared to tirzepatide (relative risk 2.78) when both were measured against placebo

Injectable GLP-1 RAs are not meal-dependent, while oral semaglutide must be taken on an empty stomach with a small amount of water

2 The medical triad Obesity, as well as DM, are conditions associated with a heightened risk of various cancers, including pancreatic, colorectal, breast, or liver cancer, and an increased mortality risk also accompanies them [8]

Additionally, there are ongoing clinical trials to further explore the effectiveness of long-acting GLP-1s in individuals with T1D and insulin resistance

However, lifestyle measures alone are less effective in maintaining adequate weight loss over time and must be augmented with weight loss medication for better outcomes and sustainability over prolonged periods

These results support the potential of GLP-1RAs as a valuable therapeutic option in managing weight outcomes in this patient population